LONDON – Cancer specialist SuperGen Inc., is taking over its privately held counterpart, Astex Therapeutics plc, in a cash and shares deal, which creates a specialist Anglo-American oncology company with a portfolio of seven drugs in clinical development, $50 million per annum in revenues, $120 million in cash and several high-profile pharma partnerships including three partnered programs in the clinic.